{"title":"使用 PCSK9 单克隆抗体(alirocumab 和 evolocumab)优化二级护理血脂门诊中欧洲动脉粥样硬化协会 (EAS) < 1.8 mmol/l 低密度脂蛋白胆固醇目标值的用药方案","authors":"","doi":"10.14738/bjhmr.106.15955","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":92231,"journal":{"name":"Journal of biomedical engineering and medical imaging","volume":"340 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic\",\"authors\":\"\",\"doi\":\"10.14738/bjhmr.106.15955\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":92231,\"journal\":{\"name\":\"Journal of biomedical engineering and medical imaging\",\"volume\":\"340 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biomedical engineering and medical imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14738/bjhmr.106.15955\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical engineering and medical imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14738/bjhmr.106.15955","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic